TNF Pharmaceuticals, Inc. (TNFA)
NASDAQ: TNFA · Real-Time Price · USD
0.3599
-0.0001 (-0.03%)
Mar 31, 2025, 3:40 PM EDT - Market open
TNF Pharmaceuticals Employees
TNF Pharmaceuticals had 6 employees as of December 31, 2023. The number of employees decreased by 3 or -33.33% compared to the previous year.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,819,489
Market Cap
991.55K
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6 | -3 | -33.33% |
Dec 31, 2022 | 9 | 0 | - |
Dec 31, 2021 | 9 | 3 | 50.00% |
Dec 31, 2020 | 6 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TNFA News
- 14 days ago - TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia - Business Wire
- 26 days ago - TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025 - Business Wire
- 4 weeks ago - TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor - Business Wire
- 2 months ago - TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment - Business Wire
- 2 months ago - TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion - Business Wire
- 3 months ago - TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs - Business Wire
- 4 months ago - TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference - Business Wire
- 6 months ago - TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market - Business Wire